Dosimetric study of interstitial brachytherapy for gynecological malignancies


Author(s): Joneetha Jones, Vinin NV, Vimal, Geetha Muttath, Silpa Ajaykumar, Akhil P Suresh

Annual incidence of Carcinoma Cervix is around 570,000 worldwide. Carcinoma Cervix is fourth leading cause for cancer death in women worldwide. Global annual incidence of Carcinoma Vagina is around 18,000. In cervical cancer patients clinical outcome has improved with intracavitary Brachytherapy. Most common site treated with Brachytherapy is Carcinoma Cervix as per the survey done by American Brachytherapy Society (ABS). In management of Carcinoma Cervix Brachytherapy plays a crucial role. Intracavitary Brachytherapy (ICBT) is the most commonly used technique. In cases where ICBT is not technically feasible or it may result in suboptimal dose distribution, Interstitial Brachytherapy (ISBT) is recommended. The most common technique for ISBT is perineal template based implant procedure.

Share this article

+44 7456035580

Editors List

  • Osamu Tanaka

    Osamu Tanaka
    Assistant Professor,
    Department of Radiation Oncology
    Asahi University Hospital
    Gifu city, Gifu, Japan

  • Maher Abdel Fattah Al-Shayeb

    Department of Surgical Sciences, Ajman University, UAE

  • Andrzej Zdziennicki

    Institute of Gynecology and Obstetrics, Medical University of Lodz, I Clinic of Gynecology and Gynecological Oncology (Lodz, Poland)

  • Krzysztof Urbanski

    Head of the Oncology Gynecology Clinic, Oncology Center - Instytut im. Maria Sklodowska Curie, Department in Krakow (Krakow, Poland)

  • Andrzej Szawlowski

    Klinika Nowotworow Gornego Odcinka Uklad Digestii, Oncology Center - Institute (Warsaw, Poland)